Pharmacogenetics of anticancer monoclonal antibodies
Open Access
- 1 January 2019
- journal article
- review article
- Published by OAE Publishing Inc. in Cancer Drug Resistance
- Vol. 2 (1) , 69-81
Abstract
Cancer Drug Resistance is an open access journal, focusing on pharmacological aspects of drug resistance and its reversal, molecular mechanisms of drug resistance and drug classes, etc. Both clinical and experimental aspects of drug resistance in cancer are included.Keywords
This publication has 78 references indexed in Scilit:
- Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responsesOncoImmunology, 2013
- Clinical Pharmacokinetics of Therapeutic Monoclonal AntibodiesClinical Pharmacokinetics, 2010
- Generation of Transgenic MiceCurrent Protocols in Cell Biology, 2009
- Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100Journal of Clinical Oncology, 2008
- Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 BlockadeJournal of Immunotherapy, 2008
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2008
- Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibitionCellular Signalling, 2007
- A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor α‐chain promoterImmunology, 2006
- The role of pharmacogenetics in cancer therapeuticsBritish Journal of Clinical Pharmacology, 2006
- The International HapMap ProjectNature, 2003